Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Repare Therapeutics Inc. (RPTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/13/2023 8-K Quarterly results
10/06/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types, genomic alterations, PARPi choice or platinum resistance Roche has included a camonsertib-based arm in its Phase 2 TAPISTRY study and its Phase 1/2 Morpheus Lung study of multiple combinations in metastatic non-small cell lung cancer Reported clinical proof of concept for lunresertib in June 2023 including achievement of monotherapy safety and tolerability primary endpoints and identification of two proposed dose/schedules Presented early lunresertib combination response data in June 2023, and expects to present further Phase 1 MYTHIC Module 2 data at a m..."
06/12/2023 4 SCHAFER CAROL (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 4 RHOADS ANN D (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 4 Morrison Briggs (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 4 Molineaux Susan (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 76,200 options to buy @ $11.66, valued at $888.5k
06/12/2023 4 Kulkarni Samarth (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 4 Foley Todd (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 4 Civik Thomas (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 4 Bonita David P (Director) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 27,200 options to buy @ $11.66, valued at $317.2k
06/12/2023 3 Molineaux Susan (Director) has filed a Form 3 on Repare Therapeutics Inc.
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/09/2023 4 Zinda Michael (EVP, Chief Scientific Officer) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Sold 6,404 shares @ $12.03, valued at $77k
Sold 2,869 shares @ $12.02, valued at $34.5k
06/07/2023 4 Zinda Michael (EVP, Chief Scientific Officer) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Sold 1,200 shares @ $12.04, valued at $14.4k
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Repare Therapeutics Reports Proof of Concept for Lunresertib in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials"
06/06/2023 144 Form 144 - Report of proposed sale of securities:
05/10/2023 144 Form 144 - Report of proposed sale of securities:
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results Reported initial camonsertib data from ongoing Phase 1/2 TRESR and Phase 1b/2 ATTACC clinical trials in a plenary oral presentation at 2023 AACR Annual Meeting Camonsertib combination therapy showed 48% CBR across tumor types regardless of choice of PARP inhibitor or platinum resistance, with a favorable safety and tolerability profile Company on track to report initial RP-6306 monotherapy data from Phase 1 MYTHIC clinical trial in June 2023 Announced the appointment of Susan Molineaux, Ph.D., and departure of Jerel Davis, Ph.D. on our Board of Directors, as well as the addition of Daniel Belanger to the senior leadership team CAMBRIDGE, Mass. & MONTREAL —May 9, 2023"
04/28/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors"
04/18/2023 8-K Quarterly results
03/10/2023 8-K Other Events  Interactive Data
03/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 8-K Quarterly results
02/14/2023 SC 13G/A PRICE T ROWE ASSOCIATES INC reports a
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A ARK Investment Management LLC reports a 5.8% stake in Repare Therapeutics Inc.
02/09/2023 SC 13G/A FMR LLC reports a 2.1% stake in REPARE THERAPEUTICS INC
02/01/2023 4 Zinda Michael (EVP, Chief Scientific Officer) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 24,550 shares @ $0
Granted 97,100 options to buy @ $12.42, valued at $1.2M
02/01/2023 4 Koehler Maria (EVP, Chief Medical Officer) has filed a Form 4 on Repare Therapeutics Inc.
Txns: Granted 26,450 shares @ $0
Granted 119,250 options to buy @ $12.42, valued at $1.5M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy